7 HealthTech Stocks Trending Now MRTX stock, AMGN stock, DNLI stock, MEIP stock, UTHR stock, LLY stock, SAGE stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent MRTX Stock Price: $71.52
Summary: Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.
Soumit Roy analyst at JonesTrading reiterates coverage on Mirati Therapeutics (MRTX) stock in the energy sector with a Buy rating and has set MRTX's stock price target at $ 110.
TipRanks.com reports that Mirati Therapeutics currently has 11 analysts offering 12-month price targets on MRTX and the consensus is a Moderate Buy rating with an average stock price target of $107.09. The most recent MRTX stock price we have is $71.52 and we are not making any MRTX forecasts at this time.
In addition, TradingView issued a Strong Sell rating for MRTX over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRTX. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRTX, please click here >>
Amgen, AMGN
Recent AMGN Stock Price: $283.29
Summary: Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
Jay Olson analyst at Oppenheimer reiterates coverage on Amgen (AMGN) stock in the energy sector with a Buy rating and has set AMGN's stock price target at $ 310.
TipRanks.com reports that Amgen currently has 15 analysts offering 12-month price targets on AMGN and the consensus is a Hold rating with an average stock price target of $261.64. The most recent AMGN stock price we have is $283.29 and we are not making any AMGN forecasts at this time.
In addition, TradingView issued a Neutral rating for AMGN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AMGN. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AMGN, please click here >>
Denali Therapeutics, DNLI
Recent DNLI Stock Price: $30.46
Summary: Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.
Charles Duncan analyst at Cantor Fitzgerald reiterates coverage on Denali Therapeutics (DNLI) stock in the energy sector with a Buy rating and has set DNLI's stock price target at $ 85.
TipRanks.com reports that Denali Therapeutics currently has 8 analysts offering 12-month price targets on DNLI and the consensus is a Strong Buy rating with an average stock price target of $61.14. The most recent DNLI stock price we have is $30.46 and we are not making any DNLI forecasts at this time.
In addition, TradingView issued a Buy rating for DNLI over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DNLI. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DNLI, please click here >>
MEI Pharma, MEIP
Recent MEIP Stock Price: $0.26
Summary: MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego.
Robyn Karnauskas analyst at Truist Financial reiterates coverage on MEI Pharma (MEIP) stock in the energy sector with a Hold rating and has set MEIP's stock price target at n/a.
TipRanks.com reports that MEI Pharma currently has 4 analysts offering 12-month price targets on MEIP and the consensus is a Moderate Buy rating with an average stock price target of $5.50. The most recent MEIP stock price we have is $0.26 and we are not making any MEIP forecasts at this time.
In addition, TradingView issued a Strong Sell rating for MEIP over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MEIP. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MEIP, please click here >>
United Therapeutics, UTHR
Recent UTHR Stock Price: $276.6
Summary: United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
Terence Flynn analyst at Morgan Stanley reiterates coverage on United Therapeutics (UTHR) stock in the energy sector with a Buy rating and has set UTHR's stock price target at $ 330.
TipRanks.com reports that United Therapeutics currently has 11 analysts offering 12-month price targets on UTHR and the consensus is a Moderate Buy rating with an average stock price target of $293.00. The most recent UTHR stock price we have is $276.6 and we are not making any UTHR forecasts at this time.
In addition, TradingView issued a Buy rating for UTHR over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on UTHR. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on UTHR, please click here >>
Eli Lilly & Co, LLY
Recent LLY Stock Price: $368.54
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Terence Flynn analyst at Morgan Stanley reiterates coverage on Eli Lilly & Co (LLY) stock in the energy sector with a Buy rating and has set LLY's stock price target at $ 446.
TipRanks.com reports that Eli Lilly & Co currently has 15 analysts offering 12-month price targets on LLY and the consensus is a Strong Buy rating with an average stock price target of $387.80. The most recent LLY stock price we have is $368.54 and we are not making any LLY forecasts at this time.
In addition, TradingView issued a Buy rating for LLY over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on LLY. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LLY, please click here >>
SAGE Therapeutics, SAGE
Recent SAGE Stock Price: $41.61
Summary: SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
Ami Fadia analyst at Needham reiterates coverage on SAGE Therapeutics (SAGE) stock in the energy sector with a Buy rating and has set SAGE's stock price target at $ 80.
TipRanks.com reports that SAGE Therapeutics currently has 10 analysts offering 12-month price targets on SAGE and the consensus is a Moderate Buy rating with an average stock price target of $47.90. The most recent SAGE stock price we have is $41.61 and we are not making any SAGE forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for SAGE over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SAGE. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SAGE, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================